Ad
related to: treatment for esbl klebsiella pneumoniae
Search results
Results From The WOW.Com Content Network
Carbapenems are the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant (primarily ertapenem-resistant) isolates have recently been reported. [16] ESBL-producing organisms may appear susceptible to some extended-spectrum cephalosporins. However, treatment with such antibiotics has been associated ...
The genus Klebsiella was named after the German microbiologist Edwin Klebs (1834–1913). [citation needed] It is also known as Friedlander's bacillum in honor of Carl Friedländer, a German pathologist, who proposed that this bacterium was the etiological factor for the pneumonia seen especially in immunocompromised individuals such as people with chronic diseases or alcoholics.
Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. [2] [3] [4] It contains meropenem, a beta-lactam antibiotic; and vaborbactam, a beta-lactamase inhibitor. [4]
[14] [15] It is active against UTIs caused by Staphylococcus saprophyticus, Enterococci (e.g., Enterococcus faecalis), Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. [15] It is a definitive treatment against susceptible extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacteria. [15]
A 2008 study at Mount Sinai identified outcomes associated with Carbapenem-resistant Klebsiella pneumoniae infections, in which patients in need of organ or stem cell transplants, mechanical ventilation, prolonged hospitalization, or prior treatment with carbapenems, had an increased probability of infection with Carbapenem-resistant K ...
The class A Klebsiella pneumoniae carbapenemase is currently the most common carbapenemase, which was first detected in North Carolina, United States, in 1996 and has since spread worldwide. [12] A later publication indicated that Enterobacteriaceae that produce KPC were becoming common in the United States. [13])
Between 2007 and 2011, the percentage of Escherichia coli isolates from Canadian hospitals that produce extended spectrum beta lactamases (ESBL) increased from 3.4% to 4.1%; among Klebsiella pneumoniae isolates ESBL producers increased from 1.5% to 4.0%.
Klebsiella is a genus of Gram-negative, oxidase-negative, rod-shaped bacteria with a prominent polysaccharide-based capsule. [3] Klebsiella is named after German-Swiss microbiologist Edwin Klebs (1834–1913). Carl Friedlander described Klebsiella bacillus which is why it was termed Friedlander bacillus for many years.